Michel Vounatsos, Biogen CEO

Not every­body is buy­ing it, but every­body is def­i­nite­ly talk­ing about a new Bio­gen buy­out re­port

A Ko­re­an busi­ness pub­li­ca­tion re­port­ed Wednes­day that Sam­sung is in the process of mak­ing a buy­out bid for Bio­gen, rais­ing equal parts skep­ti­cism and an­tic­i­pa­tion around a pos­si­ble deal.

The re­port from the Ko­rea Eco­nom­ic Dai­ly says that the Sam­sung Group – which has a long-term biosim­i­lar part­ner­ship with Bio­gen – has of­fered to ac­quire Bio­gen for some $42 bil­lion, a 20% im­prove­ment over the $35 bil­lion record­ed ahead of the re­port. That’s far less than what Bio­gen was trad­ing for when hopes of a ma­jor wind­fall from their con­tro­ver­sial Alzheimer’s drug Aduhelm still per­co­lat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.